Login to Your Account

Antisense Deal STATs Rising with Isis' Latest: AstraZeneca

By Randy Osborne
Staff Writer

Wednesday, December 12, 2012
Isis Pharmaceuticals Inc.'s latest antisense deal – this time with AstraZeneca plc, for $25 million and $6 million more possible next year, plus potential milestone payments afterward – helps the company identify more targets and pay for Phase II work with a lymphoma compound, SIS-STAT3Rx, to which the new partner also bought a license.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription